In ESCC cells, we observed that the Lyc.HCL treatment downregulated both JAK2/STAT3 and ERK signaling pathway components in a dose-dependent manner (Figure 8A). This evidence concerns the gene JAK2 and esophageal squamous cell carcinoma.